Characteristics and public availability of results of clinical trials on rare diseases registered at Clinicaltrials.gov

JAMA Internal Medicine

Volumn 176, Issue 4, 2016, Pages 556-558

  Dechartres, Agnes ^a,b,c,d   Riveros, Carolina ^a,b   Harroch, Michael ^c   Faber, Timor ^a,b   Ravaud, Philippe ^a,b,c,d,e  

^a PARIS DESCARTES UNIVERSITY   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d French Cochrane Centre   (France)

^e Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACT; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; SYSTEMATIC REVIEW; ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FACTUAL DATABASE; FINANCIAL MANAGEMENT; INTERNET; METHODOLOGY; MULTICENTER STUDY (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RARE DISEASES; REGISTER; SAMPLE SIZE; SINGLE BLIND PROCEDURE; TIME FACTOR;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; CROSS-OVER STUDIES; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; HUMANS; INTERNET; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; REGISTRIES; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; SAMPLE SIZE; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 84962753405     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.0137     Document Type: Letter

References (6)

1. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4): 267-268.
2. Haffner ME, Whitley J, MosesM. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821-825.
3. So D, Joly Y, Knoppers BM. Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry. Public Health Genomics. 2013;16(6):322-335.
4. Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: analysis of clinicaltrials.gov. Orphanet J Rare Dis. 2014; 9:170.
5. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at clinicaltrials.gov. N Engl J Med. 2015;372 (11):1031-1039.
6. Nguyen TA, Dechartres A, Belgherbi S, Ravaud P. Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol. 2013;31(24): 2998-3003.